Summary Info
No Summary

NAV Details

NAV Date : 14-Sep-12
NAV [Rs.] : 70.1
Buy/Resale Price [Rs.] : 69.44
Sell/Repurchase Price [Rs.] : 70.14
Entry Load % : NIL
Exit Load % : For investment amount less than Rs. 5 crores; 1.00% if redeemed on or before expiry of 36 months from the date of allotment. NIL if redeemed after expiry of 36 months from the date of allotmen. For investment amount greater than or equal to Rs. 5 crores - NIL.

NAV Chart

Graph: 1m |   3m |   6m |   1y |   3y
No Chart

Performance(%)

* returns above 1 yr. are annualized

No Performance

Latest Payouts

  Dividends Bonus
Ratio NA NA
Date NA NA

Investment Details

Tax Benefits : 54EA 
Min. Investment(Rs.) : 5,000.00
Increm.Investment(Rs.) : 1.00

In & Out

In
Name of the Company No of shares
No fresh investments made in
Out
Name of the Company No of shares
No investments sold out

Fund Holdings

As on 31-May-2013

Asset TypeInstrument NameIndustryNet Assets
(%)		No of SharesMkt Value
(Cr.)
Equity & Equity related Investments
Equityglaxo smithkline con healthcar ltdFMCG10.615,7114.6
Equitycadila healthcare limitedPharmaceuticals10.550,0004.6
Equitynestle india ltd.FMCG8.98,3003.9
Equitywipro ltdIT - Software8.4100,0003.7
Equityinfosys limitedIT - Software7.614,0003.3
Equitysanofi india limitedPharmaceuticals7.214,3953.1
Equitypfizer ltdPharmaceuticals6.723,3302.9
Equityoracle financials services softwareIT - Software5.17,4992.2
Equitypolaris financial technology ltd.IT - Software4.5167,0002.0
Equityhinduja global solutions limitedIT - Software4.464,6931.9
Equitymphasis ltd.IT - Software3.540,0001.5
Equitycipla ltdPharmaceuticals3.540,0001.5
Equitybharti airtel ltd.Telecomm-Service3.358,0011.4
Equitydivi laboratories ltd.Pharmaceuticals3.211,9991.4
Equityunichem laboratories ltd.Pharmaceuticals2.975,0001.3
Equityniit technologies ltd.IT - Software2.540,0001.1
Equitylupin ltdPharmaceuticals2.216,4991.0
Equitybeml ltd.Capital Goods-Non Electrical Equipment1.625,4990.7
Equityfirstsource solutions limitedIT - Software1.5700,0000.7
Equitybiocon limitedPharmaceuticals1.118,0450.5
Cash & Cash Equivalent
Cash & Bank Balance & Bank Depositscash, others-/-0.9NA0.4

My Watchlist


Schemes NAV(Rs.)
No Fund

Key Information

Fund House: 
Incorporation Date : 
Total Assets Managed (Cr.) : 
Trustee/s : 
Chairman : 
CEO / MD : 
CIO : 
President : 
Director/s : 
Compliance Officer/s : 
Investor Service Officer/s : 
Fund Manager/s : 

Other Information

Auditors : 
Registered Office : 
Contact Nos : 
Fax : 
Email :
Website : 

Fund Manager Speak

Tushar Pradhan, CIO, HSBC Mutual Fund
“Our research shows that a disciplined approach to buying companies that look attractive on this matrix provides significant longer term outperformance.”..
Vikaas Sachdeva, CEO, Edelweiss Asset Management Ltd
Kaushik Dani, Head of Equity, Peerless Funds Management Company
View all Fund Manager Speak >>

IIFL Blogs

R. Venkataraman
Unreal estate…Manic buying before a likely pan...
We have heard enough that derivatives are weapons of mass destruction. These weapons appear to have entered the real estate now. Is it a prelude to a crash?
Amar Ambani
Looking back : How Tatas served an Ace in an u...
Much hype is made over Tata Nano, the one-lakh car, from the Tata Enterprise. While the feat is indeed uncommon, the buzz deafens the other remarkable achievement of the empire in the form of the g...